Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)

Background: In a prior Phase III, randomized-withdrawal study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid and sustained normalization of mean urinary free cortisol (mUFC) in most patients (pts) with CD. Now, we report efficacy and safety results from another Phase III stud...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Gadelha, Mônica, Bex, Marie, Feelders, Richard A, Heaney, Anthony P, Auchus, Richard J, Gilis-Januszewska, Aleksandra, Witek, Przemyslaw, Belaya, Zhanna, Liao, Zhihong, Ku, Chih Hao Chen, Carvalho, Davide, Roughton, Michael, Wojna, Judi, Hofstetter, Georg, Pedroncelli, Alberto M, Snyder, Peter J
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2021
Matèries:
Neuroendocrinology and Pituitary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090763/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1055
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars